Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

BioLineRx Jumps 11% as CFO Says in Schizophrenia Drug Talks

May 23 (Bloomberg) -- BioLineRx Ltd. rose the most since February after the biopharmaceutical company said it’s in talks with larger drugmakers interested in developing an experimental schizophrenia pill.

The shares rose as much as 11 percent, the most since Feb. 6, to 1.06 shekels. They traded at 1.01 shekels at 2:52 p.m. in Tel Aviv.

The drug improved patients’ cognitive function in a mid-stage trial in 2010 and the company expects results from a more advanced study next year, Chief Financial Officer Philip Serlin said. Partnership talks will probably “heat up” then, he said.

BioLine, based in Jerusalem, says its BL-1020 drug may turn out to help patients function better in daily life while anti-psychotic medicines such as AstraZeneca Plc’s Seroquel and Johnson & Johnson’s Risperdal help quell schizophrenia symptoms such as hearing voices or violent outbursts.

To contact the reporter on this story: David Wainer in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.